ReviewBone marrow transplantation2002
Assessing minimal residual disease (MRD) in leukemia: a changing definition and concept?
Review in Bone marrow transplantation, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 46 citations in OpenAlex.
- Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay.Frontiers in oncology · 2020Article
- Evaluating measurable residual disease in acute myeloid leukemia.Blood advances · 2018Review
- SOX11 expression as a MRD molecular marker for MCL in comparison with t(11;14) and IGH rearrangement.Medical oncology (Northwood, London, England) · 2018Article
- Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.Journal of visualized experiments : JoVE · 2018Article
- Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.Frontiers in immunology · 2018Review
- HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data.BMC bioinformatics · 2017Article
- The past and future of breast cancer treatment-from the papyrus to individualised treatment approaches.Ecancermedicalscience · 2017Review
- Flow cytometric detection of minimal residual disease in B-lineage acute lymphoblastic leukemia by using "MRD lite" panel.Medical journal, Armed Forces India · 2017Article
- Article
- Plasma-derived exosomes in acute myeloid leukemia for detection of minimal residual disease: are we ready?Expert review of molecular diagnostics · 2016Review
- Minimal residual disease detection using flow cytometry: Applications in acute leukemia.Medical journal, Armed Forces India · 2016Review
- Development of a standardized flow cytometric method to conduct longitudinal analyses of intracellular CD3ζ expression in patients with head and neck cancer.Oncology letters · 2016Article
- Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?BioMed research international · 2015Review
- Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy.Journal of clinical laboratory analysis · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The term minimal residual disease (MRD) in its currently accepted application refers to low-level disease detected in a whole variety of clinical situations. It is used to describe residual disease after suboptimal induction chemotherapy, but at the same time refers to the lowest levels of disease potentially compatible with cure or to molecularly defined relapse after long-term remission. This discussion intends to redefine MRD into some biologically relevant subcategories which may warrant their own independent terminology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.